Objective(s): Prostate cancer is the world’s leading cause of cancer and the second cause of cancer-related death in men after lung cancer. Differentiation of prostate adenocarcinoma from benign prostate lesions and hyperplasia sometimes cannot be done on the basis of morphologic findings. Considering the fact that in the prostate adenocarcinoma there is no basal cell layer, basal cell markers ...

objective(s): prostate cancer is the world’s leading cause of cancer and the second cause of cancer-related death in men after lung cancer. differentiation of prostate adenocarcinoma from benign prostate lesions and hyperplasia sometimes cannot be done on the basis of morphologic findings. considering the fact that in the prostate adenocarcinoma there is no basal cell layer, basal cell markers ...

OBJECTIVES Prostate cancer is the world's leading cause of cancer and the second cause of cancer-related death in men after lung cancer. Differentiation of prostate adenocarcinoma from benign prostate lesions and hyperplasia sometimes cannot be done on the basis of morphologic findings. Considering the fact that in the prostate adenocarcinoma there is no basal cell layer, basal cell markers can...

• The use of immunohistochemistry for basal cell markers and AMACR for the diagnosis of limited adenocarcinoma of the prostate should be used as an adjunct to the H&E diagnosis as there is false positive and negative staining with these markers. • Examples of labeling of prostate adenocarcinoma with basal cell markers include: aberrant scattered HMWCK staining of cancer cells; rarely the retent...